UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 10-K/A

(Amendment No. 1)

 

(Mark One) 

|  | þ |  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--|--------|--|-------------------------------------------------------------------------------------------|

 

For the Fiscal Year Ended December 31, 2016 

 

OR 

 

|  |  ̈ |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--|--------|--|-----------------------------------------------------------------------------------------------|

 

For the Transition Period from                  to                 

 

Commission File Number: 001-31918 

 

IDERA PHARMACEUTICALS, INC. 

(Exact name of Registrant as specified in its charter) 

 

|                                     |                |
|------------------------------------------|---------------------|
| Delaware                                 | 04-3072298          |
| (State or other jurisdiction             | (I.R.S. Employer    |
| of incorporation or organization)        | Identification No.) |
|                                     |                |
| 167 Sidney Street                        | 02139               |
| Cambridge, Massachusetts                 | (Zip Code)          |
| (Address of principal executive offices) |                |

 

(617) 679-5500 

 

(Registrant’s telephone number, including area code) 

 

Securities registered pursuant to Section 12(b) of the Act 

 

|                               |                     |                                      |
|------------------------------------|--------------------------|-------------------------------------------|
| Title of Class:                    |      | Name of Each Exchange on Which Registered |
| Common Stock, $.001 par value |                     | Nasdaq Capital Market                     |

 

Securities registered pursuant to Section 12(g) of the Act: None 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☑

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act.    Yes  ☐    No  ☑ 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days.    Yes  ☑    No  ☐ 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☑    No  ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    ☐ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): 

 

|                                        |                                          |                                      |                                                    |
|---------------------------------------------|-----------------------------------------------|-------------------------------------------|---------------------------------------------------------|
| Large accelerated filer  ☐ | Accelerated filer  ☑         | Non-accelerated filer  ☐ | Smaller reporting company  ☐ |
|                                        | (Do not check if a smaller reporting company) |                                      |

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  ☐    No   ☑ 

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $145,406,315 based on the last sale price of the registrant’s common stock as reported on the Nasdaq Capital Market on June 30, 2016. As of February 15, 2017, the registrant had 149,093,717 shares of common stock outstanding. 

 

DOCUMENTS INCORPORATED BY REFERENCE 

 

Portions of the Registrant’s Proxy Statement with respect to the Annual Meeting of Stockholders to be held on June 7, 2017 are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Form 10-K. 

 

 

			 		

----

 

Table of Contents
Explanatory Note

 

 

Idera Pharmaceuticals, Inc. (“the Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2016 (the “Annual Report”), which was originally filed with the Securities and Exchange Commission on March 15, 2017, solely to include the correct version of Exhibit 10.57, as the Annual Report inadvertently included the incorrect document as Exhibit 10.57.  There are no other changes to the Annual Report.

 

This Amendment No. 1 speaks as of the date of the original filing of the Annual Report, and the Company has not updated the disclosures contained therein to reflect any events that occurred at a later date.

 

 

 

2

 

Table of Contents
PART IV.

 

Item 15.Exhibits and Financial Statement Schedules. 

 

(a)(3)The list of Exhibits filed as a part of this report is set forth on the Exhibit Index immediately preceding such Exhibits and is incorporated herein by this reference.

3

 

Table of Contents
 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 16th day of March 2017. 

 

 

 

 

 

 

Idera Pharmaceuticals, Inc.

 

 

 

 

 

By:

/S/    VINCENT J. MILANO

 

 

Vincent J. Milano

 

 

President and

 

 

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

			 		

4

 

Table of Contents
Exhibit Index

 

 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

 

Filed

 

 

   

Filing

   

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

3.1

 

Restated Certificate of Incorporation of Idera Pharmaceuticals, Inc., as amended.

 

 

 

10-Q

 

August 6, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of Idera Pharmaceuticals, Inc.

 

 

 

S-1

 

November 6, 1995

 

33-99024

 

 

 

 

 

 

 

 

 

 

 

4.1

 

Specimen Certificate for shares of Common Stock, $.001 par value, of Idera Pharmaceuticals, Inc.

 

 

 

S-1

 

December 8, 1995

 

33-99024

 

 

 

 

 

 

 

 

 

 

 

10.1††

 

2008 Stock Incentive Plan, as amended

 

 

 

8-K

 

June 17, 2011

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.2††

 

2005 Stock Incentive Plan, as amended

 

 

 

10-Q

 

August 14, 2006

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.3††

 

Amended and Restated 1997 Stock Incentive Plan.

 

 

 

10-Q

 

May 15, 2001

 

000-27352

 

 

 

 

 

 

 

 

 

 

 

10.4††

 

1995 Director Stock Option Plan.

 

 

 

8-K

 

June 10, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.5††

 

1995 Employee Stock Purchase Plan, as amended.

 

 

 

8-K

 

June 17, 2011

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.6††

 

Non-Employee Director Nonstatutory Stock Option Agreement Granted under 1997 Stock Incentive Plan.

 

 

 

10-K

 

March 25, 2005

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.7††

 

Form of Incentive Stock Option Agreement Granted Under the 2005 Stock Incentive Plan.

 

 

 

8-K

 

June 21, 2005

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.8††

 

Form of Nonstatutory Stock Option Agreement Granted Under the 2005 Stock Incentive Plan.

 

 

 

8-K

 

June 21, 2005

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.9††

 

Form of Incentive Stock Option Agreement Granted Under the 2008 Stock Incentive Plan.

 

 

 

8-K

 

June 10, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.10††

 

Form of Nonstatutory Stock Option Agreement Granted Under the 2008 Stock Incentive Plan.

 

 

 

8-K

 

June 10, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.11††

 

Form of Nonstatutory Stock Option Agreement (Non-Employee Directors) Granted Under the 2008 Stock Incentive Plan.

 

 

 

8-K

 

June 10, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.12††

 

Form of Restricted Stock Agreement Under the 2008 Stock Incentive Plan.

 

 

 

8-K

 

June 10, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

 

5

 

Table of Contents
 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

  

Filed

  

 

   

Filing

   

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

10.13††

 

Policy on Treatment of Stock Options in the Event of Retirement, approved April 28, 2014.

 

 

 

10-Q

 

August 12, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.14††

 

Employment Agreement dated October 19, 2005 between Idera Pharmaceuticals, Inc. and Dr. Sudhir Agrawal

 

 

 

10-Q

 

November 9, 2005

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.15††

 

Amendment dated December 17, 2008 to Employment Agreement by and between Idera Pharmaceuticals, Inc. and Dr. Sudhir Agrawal dated October 19, 2005.

 

 

 

8-K

 

December 18, 2008

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.16††

 

Amended and Restated Employment Letter Agreement by and between Idera Pharmaceuticals, Inc. and Louis J. Arcudi, III, Dated December 2, 2011.

 

 

 

10-K

 

March 13, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.17††

 

Director Compensation Program

 

 

 

10-Q

 

May 12, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.18

 

First Amendment dated February 21, 2014 to Lease Agreement dated October 31, 2006 between Idera Pharmaceuticals, Inc. and ARE-MA-Region No. 23, LLC.

 

 

 

10-Q

 

May 12, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.19†

 

Development and Commercialization Agreement, dated May 1, 2014, by and between Abbott Molecular Inc. and Idera Pharmaceuticals, Inc.

 

 

 

10-Q

 

August 12, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.20††

 

Employment Letter Agreement, dated December 1, 2014, by and between Idera Pharmaceuticals, Inc. and Vincent Milano.

 

 

 

10-K

 

March 12, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.21

 

Unit Purchase Agreement by and among Idera Pharmaceuticals, Inc. and certain persons and entities listed therein, dated April 1, 1998.

 

 

 

10-K

 

April 1, 2002

 

000-27352

 

 

 

 

 

 

 

 

 

 

 

10.22

 

Registration Rights Agreement dated as of May 20, 2005 by and among Idera Pharmaceuticals, Inc., Purchasers and Pillar Investment Limited.

 

 

 

10-Q

 

August 9, 2005

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.23

 

Registration Rights Agreement, dated March 24, 2006, by and among Idera Pharmaceuticals, Inc. and the Investors named therein.

 

 

 

8-K

 

March 29, 2006

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.24

 

Registration Rights Agreement, dated March 24, 2006, by and among Idera Pharmaceuticals, Inc., Biotech Shares Ltd. and Youssef El Zein.

 

 

 

8-K

 

March 29, 2006

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

 

6

 

Table of Contents
 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

   

Filed

   

 

  

Filing

   

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

10.25

 

Amendment No. 1 to the Registration Rights Agreement dated March 24, 2006, by and among Idera Pharmaceuticals, Inc. and Biotech Shares Ltd.

 

 

 

10-Q

 

August 14, 2006

 

001-31918

10.26

 

Form of Warrant issued to Investors in Idera Pharmaceuticals, Inc.’s August 5, 2010 Financing.

 

 

 

10-Q

 

November 4, 2010

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.27††

 

Second Amendment dated December 1, 2014 to Employment Agreement by and between Idera Pharmaceuticals, Inc. and Dr. Sudhir Agrawal dated October 19, 2005.

 

 

 

10-K

 

March 12, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.28††

 

Employment Letter, dated December 12, 2014, by and between Idera Pharmaceuticals, Inc. and J. Peter Wolf, III.

 

 

 

10-K

 

March 12, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.29

 

Form of Pre-Funded Warrant issued to purchasers in Idera Pharmaceuticals, Inc.’s registered public offering on Idera Pharmaceuticals, Inc.’s registration statement on Form S-3 (File No. 333-191073).

 

 

 

8-K

 

September 26,2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.30

 

Form of Pre-Funded Warrant issued to purchasers in Idera Pharmaceuticals, Inc.’s registered public offering on Idera Pharmaceuticals, Inc.’s registration statement on Form S-3 (File No. 333-191073).

 

 

 

8-K

 

February 5, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.31

 

Convertible Preferred Stock and Warrant Purchase Agreement, dated November 4, 2011, between Idera Pharmaceuticals, Inc. and the Purchaser named therein.

 

 

 

8-K

 

November 10, 2011

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.32

 

Amendment No. 1, dated November 9, 2012, to Convertible Preferred Stock and Warrant Purchase Agreement, dated November 4, 2011, between Idera Pharmaceuticals, Inc. and the Purchaser named therein.

 

 

 

8-K

 

November 14, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.33

 

Registration Rights Agreement, November 4, 2011, between Idera Pharmaceuticals, Inc. and the Purchaser named therein.

 

 

 

8-K

 

November 10, 2011

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.34

 

Form of Warrant issued to Purchaser pursuant to Convertible Preferred Stock and Warrant Purchase Agreement, dated November 4, 2011, between Idera Pharmaceuticals, Inc. and the Purchaser named therein.

 

 

 

8-K

 

November 10, 2011

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

 

7

 

Table of Contents
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

  

Filed

  

 

  

Filing

  

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

10.35

 

Amendment No. 1, dated November 9, 2012, to Warrant, dated November 4, 2011, between Idera Pharmaceuticals, Inc. and the Registered Holder named therein.

 

 

 

8-K

 

November 14, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.36

 

Convertible Preferred Stock and Warrant Purchase Agreement, dated November 9, 2012, among Idera Pharmaceuticals, Inc. and the Purchasers named therein.

 

 

 

8-K

 

November 14, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.37

 

Registration Rights Agreement, November 9, 2012, among Idera Pharmaceuticals, Inc. and the Purchasers named therein.

 

 

 

8-K

 

November 14, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.38

 

Form of Warrant issued to each Purchaser pursuant to Convertible Preferred Stock and Warrant Purchase Agreement, dated November 9, 2012, among Idera Pharmaceuticals, Inc. and the Purchasers named therein.

 

 

 

8-K

 

November 14, 2012

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.39††

 

Employment Letter Agreement by and between Idera Pharmaceuticals, Inc. and Louis Brenner, dated January 3, 2014.

 

 

 

10-K

 

March 13, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.40

 

Lease Agreement dated October 31, 2006 between Idera Pharmaceuticals, Inc. and ARE-MA-Region No. 23, LLC.

 

 

 

10-K/A

 

May 8, 2007

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.41

 

Agreement, dated April 22, 2013, among Idera Pharmaceuticals, Inc., Pillar Pharmaceuticals I, L.P. and Pillar Pharmaceuticals II, L.P.

 

 

 

8-K

 

April 23, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.42

 

Agreement, dated April 30, 2013, among Idera Pharmaceuticals, Inc., Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P. and Participations Besancon.

 

 

 

S-1/A

 

May 1, 2013

 

333-187155

 

 

 

 

 

 

 

 

 

 

 

10.43

 

Form of Warrant issued to purchasers in Idera Pharmaceuticals, Inc.’s registered public offering on Idera Pharmaceuticals, Inc.’s registration statement on Form S-1 (File No. 333-187155).

 

 

 

10-Q

 

May 15, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.44

 

Form of Warrant issued to entities affiliated with Pillar Invest Corporation in Idera Pharmaceuticals, Inc.’s registered public offering on Idera Pharmaceuticals, Inc.’s registration statement on Form S-1 (File No. 333-187155).

 

 

 

10-Q

 

May 15, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

 

8

 

Table of Contents
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

   

Filed

   

 

   

Filing

   

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

10.45

 

Form of Pre-Funded Warrant issued to purchasers in Idera Pharmaceuticals, Inc.’s registered public offering on Idera Pharmaceuticals, Inc.’s registration statement on Form S-1 (File No. 333-187155).

 

 

 

10-Q

 

May 15, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.46††

 

2013 Stock Incentive Plan, as amended.

 

 

 

8-K

 

June 13, 2014

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.47††

 

Form of Incentive Stock Option Agreement granted under the 2013 Stock Incentive Plan.

 

 

 

8-K

 

July 29, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.48††

 

Form of Nonstatutory Stock Option Agreement granted under the 2013 Stock Incentive Plan.

 

 

 

8-K

 

July 29, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.49††

 

Form of Nonstatutory Stock Option Agreement (Non-Employee Directors) granted under the 2013 Stock Incentive Plan.

 

 

 

8-K

 

July 29, 2013

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.50††

 

Employment Letter, dated January 26, 2015, by and between Idera Pharmaceuticals, Inc. and Clayton Fletcher.

 

 

 

10-Q

 

May 11, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.51††

 

Consulting Agreement, dated January 30, 2015, by and between Idera Pharmaceuticals, Inc. and Robert D. Arbeit, M.D.

 

 

 

10-Q

 

May 11, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.52

 

Registration Rights Agreement, dated February 9, 2015, among Idera Pharmaceuticals, Inc. and the Selling Stockholders named therein.

 

 

 

8-K

 

February 9, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.53††

 

Amendment to 2013 Stock Incentive Plan, as amended.

 

 

 

8-K

 

June 11, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.54††

 

Form of Inducement Stock Option Award – Nonstatutory Stock Option Agreement.

 

 

 

10-Q

 

November 6, 2015

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.55††

 

Employment Letter, dated June 5, 2015, by and between Idera Pharmaceuticals, Inc. and Mark J. Casey.

 

 

 

10-Q

 

May 9, 2016

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.56*

 

License Agreement, dated November 28, 2016, by and between Idera Pharmaceuticals, Inc. and Vivelix Pharmaceuticals, Ltd.

 

 

 

10-K

 

March 15, 2017

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

10.57

 

Second Amendment dated November 17, 2016 to Lease Agreement dated October 31, 2006 between Idera Pharmaceuticals, Inc. and ARE-MA-Region No. 23, LLC.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

10-K

 

March 15, 2017

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

10-K

 

March 15, 2017

 

001-31918

9

 

Table of Contents
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Incorporated by Reference to

Exhibit

   

 

   

Filed

   

 

   

Filing

   

SEC File

Number

 

Description

 

Herewith

 

Form

 

Date

 

No.

32.2

 

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

10-K

 

March 15, 2017

 

001-31918

 

 

 

 

 

 

 

 

 

 

 

 

†        Confidential treatment granted as to certain portions, which are omitted and filed separately with the Commission. 

††      Management contract or compensatory plan or arrangement required to be filed as an Exhibit to the Annual Report on Form 10-K.

*Confidential treatment requested as to certain portions, which portions are omitted and filed separately with the Commission.

 

 

10